Jefferies Group LLC bought a new position in shares of AxoGen, Inc. (NASDAQ:AXGN) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 67,655 shares of the medical equipment provider’s stock, valued at approximately $1,915,000. Jefferies Group LLC owned approximately 0.20% of AxoGen at the end of the most recent quarter.
A number of other hedge funds have also recently added to or reduced their stakes in the business. BlackRock Inc. grew its holdings in shares of AxoGen by 29.7% in the 4th quarter. BlackRock Inc. now owns 1,785,891 shares of the medical equipment provider’s stock valued at $50,540,000 after acquiring an additional 408,596 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of AxoGen by 9.0% in the 2nd quarter. Vanguard Group Inc. now owns 1,223,069 shares of the medical equipment provider’s stock valued at $20,486,000 after acquiring an additional 101,245 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of AxoGen by 34.6% in the 4th quarter. Bank of New York Mellon Corp now owns 849,993 shares of the medical equipment provider’s stock valued at $24,054,000 after acquiring an additional 218,430 shares in the last quarter. Next Century Growth Investors LLC lifted its stake in AxoGen by 1.7% in the 4th quarter. Next Century Growth Investors LLC now owns 667,642 shares of the medical equipment provider’s stock valued at $18,894,000 after purchasing an additional 10,876 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its stake in AxoGen by 63.5% in the 4th quarter. Renaissance Technologies LLC now owns 657,800 shares of the medical equipment provider’s stock valued at $18,616,000 after purchasing an additional 255,400 shares during the last quarter. Hedge funds and other institutional investors own 68.01% of the company’s stock.
Shares of AxoGen, Inc. (NASDAQ AXGN) opened at $35.15 on Wednesday. The company has a current ratio of 4.07, a quick ratio of 3.53 and a debt-to-equity ratio of 0.79. The stock has a market cap of $1,188.42, a P/E ratio of -117.16 and a beta of 0.10. AxoGen, Inc. has a 1 year low of $9.70 and a 1 year high of $35.45.
Several equities research analysts recently issued reports on AXGN shares. Jefferies Group started coverage on shares of AxoGen in a research note on Thursday, November 30th. They issued a “buy” rating and a $35.00 target price for the company. Cantor Fitzgerald set a $37.00 target price on shares of AxoGen and gave the company a “buy” rating in a research note on Monday, January 8th. BidaskClub downgraded shares of AxoGen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, January 11th. Lake Street Capital set a $38.00 target price on shares of AxoGen and gave the company a “buy” rating in a research note on Friday, March 2nd. Finally, Wedbush reiterated a “buy” rating and issued a $27.00 target price (up from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $31.71.
In other AxoGen news, CFO Jamie Mark Grooms sold 10,300 shares of the firm’s stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $26.21, for a total transaction of $269,963.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 169,407 shares of company stock valued at $4,593,013 over the last 90 days. Company insiders own 9.33% of the company’s stock.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.